Gene · 4437
Papers3,191
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 3,191
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition. | Int J Clin Oncol | 2023 | 37599324 | PubTator, text mining | PubMed |
| MicroRNAs as the pivotal regulators of cisplatin resistance in head and neck cancers. | Cancer Cell Int | 2023 | 37587481 | PubTator, text mining | PubMed |
| Epigenetic insights into colorectal cancer: comprehensive genome-wide DNA methylation profiling of 294 patients in Korea. | BMB Rep | 2023 | 37574809 | PubTator, text mining | PubMed |
| Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice. | Cancers (Basel) | 2023 | 37568746 | PubTator, text mining | PubMed |
A Randomized Trial Comparing the Effectiveness of Pre-test Genetic Counseling Using an Artificial Intelligence Automated Chatbot and Traditional In-person Genetic Counseling in Women Newly Diagnosed with Breast Cancer. | Ann Surg Oncol | 2023 | 37567976 | PubTator, text mining | PubMed |
| Copy number architectures define treatment-mediated selection of lethal prostate cancer clones. | Nat Commun | 2023 | 37563129 | PubTator, text mining | PubMed |
| Prospects of nanoparticle-based radioenhancement for radiotherapy. | Mater Horiz | 2023 | 37555747 | PubTator, text mining | PubMed |
| [The Mechanisms of Piceatannol in Inhibiting the Malignant Biological Characteristics of Acute Myeloid Leukemia Cells]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2023 | 37551466 | PubTator, text mining | PubMed |
| FAN1 removes triplet repeat extrusions via a PCNA- and RFC-dependent mechanism. | Proc Natl Acad Sci U S A | 2023 | 37549289 | PubTator, text mining | PubMed |
| [Testing deficient mismatch repair and microsatellite instability : A focused update. German version]. | Pathologie (Heidelb) | 2023 | 37548948 | PubTator, text mining | PubMed |
| The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours. | Lancet Reg Health West Pac | 2023 | 37547050 | PubTator, text mining | PubMed |
| Molecular characterization of colorectal adenoma and colorectal cancer via integrated genomic transcriptomic analysis. | Front Oncol | 2023 | 37546388 | PubTator, text mining | PubMed |
| Key role of phosphorylation sites in ATPase domain and Linker region of MLH1 for DNA binding and functionality of MutLα. | Sci Rep | 2023 | 37532794 | PubTator, text mining | PubMed |
| The Role of miRNAs in the Development, Proliferation, and Progression of Endometrial Cancer. | Int J Mol Sci | 2023 | 37511248 | PubTator, text mining | PubMed |
| DNA Damage Repair Pathways in Prostate Cancer: A Narrative Review of Molecular Mechanisms, Emerging Biomarkers and Therapeutic Targets in Precision Oncology. | Int J Mol Sci | 2023 | 37511177 | PubTator, text mining | PubMed |
| Germline CNV Detection through Whole-Exome Sequencing (WES) Data Analysis Enhances Resolution of Rare Genetic Diseases. | Genes (Basel) | 2023 | 37510394 | PubTator, text mining | PubMed |
| EMAST Type of Microsatellite Instability-A Distinct Entity or Blurred Overlap between Stable and MSI Tumors. | Genes (Basel) | 2023 | 37510378 | PubTator, text mining | PubMed |
| Tumor-Associated Macrophages Affect the Tumor Microenvironment and Radioresistance via the Upregulation of CXCL6/CXCR2 in Hepatocellular Carcinoma. | Biomedicines | 2023 | 37509721 | PubTator, text mining | PubMed |
| Landscape of Genetic Mutations in Appendiceal Cancers. | Cancers (Basel) | 2023 | 37509254 | PubTator, text mining | PubMed |
| The microbial genotoxin colibactin exacerbates mismatch repair mutations in colorectal tumors. | Neoplasia | 2023 | 37499275 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4437/papers?page=13